Your browser doesn't support javascript.
loading
Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination.
Francesca Colavita; Silvia Meschi; Cesare Ernesto Maria Gruber; Martina Rueca; Francesco Vairo; Giulia Matusali; Daniele Lapa; Emanuela Giombini; Gabriella De Carli; Martina Spaziante; Francesco Messina; Giulia Bonfiglio; Fabrizio Carletti; Eleonora Lalle; Lavinia Fabeni; Giulia Berno; Vincenzo Puro; Antonino Di Caro; Barbara Bartolini; Giuseppe Ippolito; Maria Rosaria Capobianchi; Concetta Castilletti; - INMI Covid-19 laboratory surveillance team.
Afiliación
  • Francesca Colavita; National Institute for Infectious Diseases "L. Spallanzani" - INMI
  • Silvia Meschi; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Cesare Ernesto Maria Gruber; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Martina Rueca; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Francesco Vairo; National Institute for Infectious Diseases "L. Spallanzani" - INMI
  • Giulia Matusali; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Daniele Lapa; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Emanuela Giombini; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Gabriella De Carli; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Martina Spaziante; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Francesco Messina; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Giulia Bonfiglio; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Fabrizio Carletti; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Eleonora Lalle; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Lavinia Fabeni; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Giulia Berno; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Vincenzo Puro; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Antonino Di Caro; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Barbara Bartolini; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Giuseppe Ippolito; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Maria Rosaria Capobianchi; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • Concetta Castilletti; National Institute for Infectious Diseases "L. Spallanzani"-INMI
  • - INMI Covid-19 laboratory surveillance team;
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21263882
ABSTRACT
Coronavirus disease 2019 (COVID-19) vaccines are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study describes 94 infections (47.9% symptomatic, 52.1% asymptomatic), occurred in Lazio Region (Central Italy) in the first trimester 2021, after first or second dose of mRNA BNT162b2 vaccine. Median viral load at diagnosis was independent from number and time of vaccine dose administration, despite the higher proportion of samples with low viral load observed in fully vaccinated individuals. More importantly, infectious virus was cultured from NPS collected from both asymptomatic and symptomatic vaccinated individuals, suggesting that, at least in principle, they can transmit the infection to susceptible people. The majority of the post-vaccine infections here reported, showed pauci/asymptomatic clinical course, confirming the impact of vaccination on COVID-19 disease. Most cases (78%) showed infection in presence of neutralizing antibodies at the time of infection diagnosis, presumably attributable to vaccination, due to the concomitant absence of anti-N IgG in most cases. The proportion of post-vaccine infections attributed either to Alpha and Gamma VOCs was similar to the proportion observed in the contemporary unvaccinated population in Lazio region. In addition, mutational analysis did not suggest enrichment of a defined set of Spike protein substitutions depending on the vaccination status. Characterization of host and virus factors associated with vaccine breakthrough, coupled with intensive and continuous monitoring of involved viral strains, is crucial to adopt informed vaccination strategies.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint